SEAGULL HEALTH
Your health,We care!
Its core features are potent and highly selective ALK inhibition, excellent brain metastasis control, multi-target efficacy expansion and controllable safety.
AuthenticGuaranteeFast DeliveryPrivacy At present, Ensartinib has been approved for marketing in both China and the United States, included in the recommendations of the American NCCN Guidelines. It has become an important treatment option for ALK-positive NSCLC, and also provides a new therapeutic direction for refractory lung cancer subtypes such as METex14 mutation.
Ensartinib is a targeted therapy for ALK-positive non-small cell lung cancer (NSCLC). Common adverse reactions include gastrointestinal symptoms, abno···【Read More】
Update: 15 Jan,2026Source: Haiou HealthViews: 191
The recommended usual dose of ensartinib is 225 mg once daily, to be taken orally on an empty stomach (1 hour before a meal or 2 hours after a meal). ···【Read More】
Update: 15 Jan,2026Source: Haiou HealthViews: 184
Ensartinib is a second-generation anaplastic lymphoma kinase (ALK) targeted drug, primarily indicated for the treatment of ALK-positive non-small cell···【Read More】
Update: 14 Jan,2026Source: Haiou HealthViews: 184
Ensartinib is an anaplastic lymphoma kinase (ALK)-targeted oral capsule developed by Hutchison MediPharma. It was first approved for marketing in Chin···【Read More】
Update: 14 Jan,2026Source: Haiou HealthViews: 230
The standard dosage of Ensartinib is 225 mg orally once daily, with or without food, swallowed whole at a fixed time every day. Treatment does not sta···【Read More】
Update: 21 Sep,2026Source: Haiou HealthViews: 95
Ensartinib is a targeted drug classified as an ALK inhibitor, primarily used for the treatment of ALK fusion-positive locally advanced or metastatic n···【Read More】
Update: 20 Sep,2026Source: Haiou HealthViews: 101
Ensartinib is a novel and potent domestically developed targeted drug classified as a second-generation ALK inhibitor. It primarily targets patients w···【Read More】
Update: 20 Sep,2026Source: Haiou HealthViews: 97
Ensartinib is an ALK inhibitor targeted therapy primarily used to treat locally advanced or metastatic non-small cell lung cancer with ALK gene fusion···【Read More】
Update: 17 Sep,2026Source: Haiou HealthViews: 97
Ensartinib is a targeted therapy drug designed to target specific gene mutations, and it is mainly indicated for patients with locally advanced or met···【Read More】
Update: 15 Jan,2026Source: Haiou HealthViews: 150
Ensartinib is a targeted therapy drug indicated for ALK-positive non-small cell lung cancer (NSCLC). It must be administered strictly in accordance wi···【Read More】
Update: 15 Jan,2026Source: Haiou HealthViews: 170
Ensartinib is a targeted therapy drug primarily indicated for patients with advanced anaplastic lymphoma kinase (ALK) fusion-positive non-small cell l···【Read More】
Update: 14 Jan,2026Source: Haiou HealthViews: 189
Copyright 2024 @ haiouhealth.com All right reserved Seagull health | Bigbear Pharmaceutical | Lucius Pharmaceuticals | 老挝全球药房
